Longitude Capital

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.

Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Solta Medical - Medical Aesthetic Devices > Splash

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Aptus Endosystems, Inc., a medical device company, develops, manufactures, and distributes endograft anchoring systems for endovascular aneurysm repair (EVAR). The company offers Heli-FX EndoAnchor system for the treatment of abdominal and thoracic aortic aneurysmal disease; and Heli-FX thoracic endoanchor system, a longer delivery device to enhance the long term durability of thoracic EVAR. It also provides Aptus TourGuide, a steerable sheath that enables quick access and delivery of peripheral vascular products. The company serves customers in the United States, Germany, Italy, the Netherlands, and the United Kingdom. It offers its products through distributors. The company was incorporated in 2002 and is based in Sunnyvale, California. As of June 19, 2015, Aptus Endosystems, Inc. operates as a subsidiary of Medtronic plc.

Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

CeriBell, Inc. designs and manufactures medical devices for acquisition and interpreting electroencephalography (EEG) data in patients with various neurological conditions. It offers Ceribell EEG system that includes Ceribell EEG Headband that allows healthcare providers to accommodate various hair types and head sizes; and Ceribell EEG Recorder, a pocket-sized, battery operated recorder that provides clinical quality EEG and on-device EEG display. It serves medical staff in hospital ICUs, inpatient units, and emergency departments. CeriBell, Inc. was formerly known as Brain Stethoscope, Inc. The company was incorporated in 2014 and is based in Mountain View, California.

CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Whitehill develops software designed to take data and information created in the pre-Internet era and use XML (Extensible Markup Language) to allow the material to be posted on the Internet.

Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

Velomedix, Inc. is a therapeutic hypothermia company in the United States. Its therapeutic hypothermia technology offers a novel solution for the protection of the body's organs during ischemic or inflammatory insults. Velomedix, Inc. is based in Menlo Park, California.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Crownwheel Partners provides liquidity and financing solutions to royalty owners and companies in the global healthcare sector. Founded in 2013, CrownWheel invests in commercial and late-stage products through the full or partial monetization of royalty streams, revenue participation, the purchase of structured debt and equity, and the acquisition of legacy or non-core products.

Dascena, Inc develops algorithm software for diagnostics and biomarkers. It provides AlgoDiagnostics, for acute decompensation, sepsis, and acute kidney injury autonomously processes electronic health record data to enable early intervention. The company was incorporated in 2018 and is based in Oakland, California.

ALPHAEON Corporation develops beauty, wellness, and lifestyle products for customers in the United States and internationally. It offers nutritional supplements that include Omega-3 supplements for skin wellness; beauty products for improving the appearance of fine lines and wrinkles, dull and dry skin, and thinning eyelashes; and PRN Omega-3 products for eye health. The company also provides plastic surgery, ophthalmology, and dermatology financing services. It offers its products online. ALPHAEON Corporation was incorporated in 2012 and is based in Irvine, California.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Solta Medical - Medical Aesthetic Devices > Splash

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.

PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Amphora Medical is a Minnesota-based developer of medical devices and instruments. The company is currently working on a novel cystoscopic device that has the potential to improve bladder function and quality of life for people with Overactive Bladder Syndrome (OAB). It was founded in 2011 and is headquartered in Minneapolis, Minnesota, United States.

InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and is based in Trevose, Pennsylvania.

IntelyCare offers a digital workforce augmentation platform that combines a gig-model application with advanced data science to optimize staff resources and close the widening gap between workforce supply and demand. IntelyCare is revolutionizing the antiquated healthcare staffing market, filling nursing shifts at three times the industry average and giving post-acute facilities the tools to predict and manage staffing needs. The company’s engaging mobile app empowers nursing professionals with access to flexible, on-demand work opportunities, reducing burnout and attrition while increasing productivity.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.

LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.

Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.

Sympara Medical is a medical company that focuses on developing novel therapies for hypertension. It was established in 2012 and is based in San Francisco, California.

At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Aptus Endosystems, Inc., a medical device company, develops, manufactures, and distributes endograft anchoring systems for endovascular aneurysm repair (EVAR). The company offers Heli-FX EndoAnchor system for the treatment of abdominal and thoracic aortic aneurysmal disease; and Heli-FX thoracic endoanchor system, a longer delivery device to enhance the long term durability of thoracic EVAR. It also provides Aptus TourGuide, a steerable sheath that enables quick access and delivery of peripheral vascular products. The company serves customers in the United States, Germany, Italy, the Netherlands, and the United Kingdom. It offers its products through distributors. The company was incorporated in 2002 and is based in Sunnyvale, California. As of June 19, 2015, Aptus Endosystems, Inc. operates as a subsidiary of Medtronic plc.

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

Solta Medical - Medical Aesthetic Devices > Splash

Polares Medical S.A. manufactures and markets medical device to reduce or eliminate mitral valve regurgitation. The company is based in Ecublens, Switzerland, with additional office in Palo Alto, California.

Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome. The company's products in the clinical pipeline include JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-8, a formulation incorporating a benzodiazepine, for the treatment of acute repetitive seizure clusters in refractory epilepsy patients. Its pipeline also comprise JZP-7, a formulation incorporating a dopamine agonist for the treatment of restless legs syndrome; and JZP-2, a formulation of a benzodiazepine for the acute treatment of panic attacks associated with panic disorder. The company has a product development and license agreement with Antares Pharma, Inc. Jazz Pharmaceuticals was founded in 2003 and is headquartered in Palo Alto, California.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Cortica Inc. provides neurological therapies for children with autism and other neurodevelopmental challenges. It offers customized treatment programs for children with autism based on an in-depth understanding of the child's neurobiology and developmental profile. The company provides in-home, in-clinic, and telehealth services. Cortica Inc. was incorporated in 2014 and is based in San Diego, California. It has centers in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village, California.

They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America. The company was founded in 2012 and is headquartered in Palo Alto, California.

RxSight, Inc. develops light adjustable lens that enables doctors and patients to predictably optimize vision after cataract surgery through an office based intraocular lens enhancement. It offers RxLAL that enables surgeons to precisely reshape the lens based on the exact amount of visual correction and optimization needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was founded in 1997 and is based in Aliso Viejo, California.

Theseus Pharmaceuticals is a Technology based company.

Cohere Health is a patient-journey-focused software-as-a-service company on a mission to significantly improve the experience of patients, providers and health plans; increase the quality of care delivered; lower total cost of care; and increase transparency across the patient care journey.

CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Zavante Therapeutics, Inc., a biopharmaceutical company, engages in developing medicines for the treatment of diseases that affect patients in the hospital setting. Its products in pipeline include ZOLYD, an investigational injectable antibiotic under development to combat serious and life-threatening infections, including those due to multi-drug resistant gram-negative and gram-positive bacteria. The company was incorporated in 2013 and is based in San Diego, California. As of July 24, 2018, Zavante Therapeutics, Inc. operates as a subsidiary of Nabriva Therapeutics plc.

ALPHAEON Corporation develops beauty, wellness, and lifestyle products for customers in the United States and internationally. It offers nutritional supplements that include Omega-3 supplements for skin wellness; beauty products for improving the appearance of fine lines and wrinkles, dull and dry skin, and thinning eyelashes; and PRN Omega-3 products for eye health. The company also provides plastic surgery, ophthalmology, and dermatology financing services. It offers its products online. ALPHAEON Corporation was incorporated in 2012 and is based in Irvine, California.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.

Cydan II, Inc. is a drug accelerator which develops therapies for rare genetic diseases. The company evaluates products for treating rare genetic diseases and further development by biotechnology companies. The company conducts de-risking studies on diseases and disorders with a genetic etiology. It develops therapies for Niemann-Pick Disease Type C and IMR-687, a treatment for sickle cell disease. The company was founded in 2013 and is based in Cambridge, Massachusetts.

AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

Encore Dermatology is a privately held fully-integrated dermatology company that provides prescription therapies and medical devices to dermatologists. It provides a range of medical dermatology products, treating a number of topical disease states that enable patients to get improved skin care and treatment with ease. Encore Dermatology was established in 2015 and is headquartered in Malvern, Pennsylvania.

Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

ALPHAEON Corporation develops beauty, wellness, and lifestyle products for customers in the United States and internationally. It offers nutritional supplements that include Omega-3 supplements for skin wellness; beauty products for improving the appearance of fine lines and wrinkles, dull and dry skin, and thinning eyelashes; and PRN Omega-3 products for eye health. The company also provides plastic surgery, ophthalmology, and dermatology financing services. It offers its products online. ALPHAEON Corporation was incorporated in 2012 and is based in Irvine, California.

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Molecular Templates Inc. (MTI) is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The company has a lead compound for melanoma that is expected to enter into clinical trials in the next two years and is developing additional compounds against a variety of other cancers.

Eargo, Inc., a consumer-focused medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.

Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.

CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

BAROnova, Inc., a clinical-stage medical-device company, engages in developing non-surgical non-pharmacologic devices to induce weight loss. It develops TransPyloric Shuttle, a device that is inserted into the stomach through the mouth using a simple endoscopic procedure, as well as causes a patient’s stomach to fill up faster, stay full longer, and delay gastric emptying. BAROnova, Inc. was formerly known as Polymorfix, Inc. BAROnova, Inc. was founded in 2006 and is based in San Jose, California.

PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Venus Concept is a progressive thinking company driven by their passion to create cutting edge technologies and products. While resting on strong ethical morals, they push boundaries in order to create new standards in the medical aesthetics industry. Led by a team of experienced executives and researchers, world renowned for their achievements in the medical aesthetics industry, Venus Concept is delivering the promise of a more effective, more pleasant and more profitable experience.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.

At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.

Epirium Bio, Inc. develops compounds for treatment of cardiovascular diseases and metabolic syndrome. Epirium Bio, Inc. was formerly known as Cardero Therapeutics, Inc. The company was incorporated in 2008 and is based in San Diego, California.

Practice Fusion is a cloud-based electronic health records company in the U.S. for independent practices. Its mission is to connect doctors, patients, and data to drive better health and save lives. The company was founded in 2005 and is headquartered in San Francisco, California.

Murj is a Santa Cruz, California digital health company dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.